Background Pathological destruction of blood-brain barrier (BBB) has been thought to be the initial key event in the process of developing multiple sclerosis (MS). The purpose of the present study was to clarify the possible molecular mechanisms responsible for the malfunction of BBB by sera from relapse-remitting MS (RRMS) and secondary progressive MS (SPMS) patients. Methods We evaluated the effects of sera from the patients in the relapse phase of RRMS (RRMS-R), stable phase of RRMS (RRMS-S) and SPMS on the expression of tight junction proteins and vascular cell adhesion protein-1 (VCAM-1), and on the transendothelial electrical resistance (TEER) in human brain microvascular endothelial cells (BMECs). Results Sera from the RRMS-R or SPMS patients decreased the claudin-5 protein expression and the TEER in BMECs. In RRMS-R, this effect was restored after adding an MMP inhibitor, and the MMP-2/9 secretion by BMECs was significantly increased after the application of patients' sera. In SPMS, the immunoglobulin G (IgG) purified from patients' sera also decreased the claudin-5 protein expression and the TEER in BMECs. The sera and purified IgG from all MS patients increased the VCAM-1 protein expression in BMECs. Conclusions The up-regulation of autocrine MMP-2/9 by BMECs after exposure to sera from RRMS-R patients or the autoantibodies against BMECs from SPMS patients can compromise the BBB. Both RRMS-S and SPMS sera increased the VCAM-1 expression in the BBB, thus indicating that targeting the VCAM-1 in the BBB could represent a possible therapeutic strategy for even the stable phase of MS and SPMS.
References
[1]
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343: , 938–52.
[2]
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: , 907–11.
[3]
Cotton F, Weiner HL, Jolesz FA, Guttmann CR (2003) MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60: , 640–6.
[4]
Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, et al.. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: , 296–304.
[5]
Anderson VM, Fox NC, Miller DH (2006) Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 23: , 605–18.
[6]
Zivadinov R, Cox JL (2007) Neuroimaging in multiple sclerosis. Int Rev Neurobiol 79: , 449–74.
[7]
Lassmann H (2007) New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 7: , 239–44.
[8]
Bradl M, Lassmann H (2009) Progressive multiple sclerosis. Semin Immunopathol 31: , 455–65.
[9]
Takeshita Y, Ransohoff RM (2012) Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 248: , 228–39.
[10]
Alvarez JI, Cayrol R, Prat A (2011) Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 1812: , 252–64.
[11]
Larochelle C, Alvarez JI, Prat A (2011) How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett 585: , 3770–80.
[12]
Kirk J, Plumb J, Mirakhur M, McQuaid S (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 201: , 319–27.
[13]
Plumb J, McQuaid S, Mirakhur M, Kirk J (2002) Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 12: , 154–69.
[14]
Leech S, Kirk J, Plumb J, McQuaid S (2007) Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 33: , 86–98.
[15]
Leppert D, Ford J, Stabler G, Grygar C, Lienert C, et al.. (1998) Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121: , 2327–34.
[16]
Shimizu F, Kanda T (2013) The Blood-Brain Barrier in Neuroinflammation. In Suzumura A, Ikenaka K, editors. Neuron-Glia Interaction in Neuroinflammation. New York, NY: Springer Science+Business Media New York. pp. 157–79.
[17]
Murphy G, Kn？uper V (1997) Relating matrix metalloproteinase structure to function: why the “hemopexin” domain? Matrix Biol 15: , 511–8.
[18]
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al.. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: , 292–302.
[19]
Sano Y, Shimizu F, Abe M, Maeda T, Kashiwamura Y, et al.. (2010) Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 225: , 519–28.
[20]
Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, et al.. (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161: , 653–60.
[21]
Abbott NJ, R？nnb？ck L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: , 41–53.
[22]
Engelhardt B (2010) T cell migration into the central nervous system during health and disease: Different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol 1: , 79–93.
[23]
Minagar A, Ostanin D, Long AC, Jennings M, Kelley RE, et al.. (2003) Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult Scler 9: , 235–8.
[24]
Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, et al.. (2006) Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 65: , 855–65.
[25]
Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, et al.. (2012) Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 83: , 288–97.
[26]
Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR (2009) VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A 106: , 1977–82.
[27]
Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, et al.. (2012) Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 122: , 2454–68.
[28]
Su JJ, Osoegawa M, Matsuoka T, Minohara M, Tanaka M, et al.. (2006) Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 243: , 21–30.
[29]
Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, et al.. (2009) Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler 15: , 316–22.
[30]
Gijbels K, Galargy RE, Steinman L (1994) Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 94: , 2177–82.
[31]
Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31: , 247–69.
[32]
Zamvil SS, Steinman L (2003) Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 38: , 685–8.
[33]
Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: , 178–201.
[34]
Brosnan CF, Cannella B, Battistini L, Raine CS (1995) Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 45: , S16–21.
[35]
Engelhardt B, Kappos L (2008) Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 5: , 16–22.
[36]
Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, et al.. (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68: , 1390–401.
[37]
Cadavid D, Jurgensen S, Lee S (2013) Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One 8: , e53297.
